GlassScriptPhysician profile
Albert Q Chow
NPI 1952745390
$2,190.02
in general payments reported to CMS, 2019-2025
15 companies · $281 in 2025
The $281 reported for 2025 was more than what 83% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $225 · 2021: $294 · 2022: $274 · 2023: $662 · 2024: $329 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $521.96 | 2021-2023 | Lupkynis |
| Glaxosmithkline, LLC. | $504.76 | 2020-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $247.36 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $176.90 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $137.17 | 2019-2021 | |
| Abbvie INC. | $128.38 | 2021-2024 | |
| Ucb, INC. | $124.99 | 2025 | Bimzelx |
| Amgen INC. | $78.62 | 2023 | Enbrel |
| Genentech USA, INC. | $67.69 | 2021-2024 | Actemra |
| Azurity Pharmaceuticals, INC. | $60.04 | 2020-2023 | Xatmep |
| Pharming Healthcare, INC. | $40.58 | 2023 | Joenja |
| Takeda Pharmaceuticals U.S.A., INC. | $34.94 | 2023 | Takhzyro |
| Biocon Biologics INC | $27.29 | 2023 | Hulio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.33 | 2023 | Cyltezo |
| Pfizer INC. | $18.01 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.